Coadministration of nano-curcumin alleviated doxorubicin-induced cardiotoxicity in animal models through antioxidant, anti-inflammatory, and antiapoptotic mechanisms, with higher efficacy than free curcumin.
Systematic Review (n=10)
Does nano-curcumin alleviate doxorubicin-induced cardiotoxicity in animal models?
Nano-curcumin shows potential as a cardioprotective agent against doxorubicin-induced cardiotoxicity in preclinical models, with greater efficacy than free curcumin.
Although the chemotherapeutic drug, doxorubicin, is commonly used to treat various malignant tumors, its clinical use is restricted because of its toxicity especially cardiotoxicity. The use of curcumin may alleviate some of the doxorubicin-induced cardiotoxic effects. Especially, using the nano-formulation of curcumin can overcome the poor bioavailability of curcumin and enhance its physicochemical properties regarding its efficacy. In this study, we systematically reviewed the potential cardioprotective effects of nano-curcumin against the doxorubicin-induced cardiotoxicity. A systematic search was accomplished based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for the identification of all relevant articles on "the role of nano-curcumin on doxorubicin-induced cardiotoxicity" in the electronic databases of Scopus, PubMed, and Web of Science up to July 2021. One hundred and sixty-nine articles were screened following a predefined set of inclusion and exclusion criteria. Ten eligible scientific papers were finally included in the present systematic review. The administration of doxorubicin reduced the body and heart weights of mice/rats compared to the control groups. In contrast, the combined treatment of doxorubicin and nano-curcumin increased the body and heart weights of animals compared with the doxorubicin-treated groups alone. Furthermore, doxorubicin could significantly induce the biochemical and histological changes in the cardiac tissue; however, coadministration of nano-curcumin formulation demonstrated a pattern opposite to the doxorubicin-induced changes. The coadministration of nano-curcumin alleviates the doxorubicin-induced cardiotoxicity through various mechanisms including antioxidant, anti-inflammatory, and antiapoptotic effects. Also, the cardioprotective effect of nano-curcumin formulation against doxorubicin-induced cardiotoxicity was higher than free curcumin.
Moutabian et al. (Wed,) conducted a systematic review in Doxorubicin-induced cardiotoxicity (n=10). Nano-curcumin vs. Doxorubicin alone and free curcumin was evaluated on Cardioprotective effects (body and heart weights, biochemical and histological changes). Coadministration of nano-curcumin alleviated doxorubicin-induced cardiotoxicity in animal models through antioxidant, anti-inflammatory, and antiapoptotic mechanisms, with higher efficacy than free curcumin.